2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
Clinical Infectious Diseases·
- DOI
- 10.1093/cid/ciw360
- PMID
- 27470238
- PMCID
- —
- OpenAlex
- W2479157738
- Study type
- Guideline
- Publisher
- Oxford University Press (OUP)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The guideline emphasizes that residence in and recent travel to endemic areas are critical for accurate recognition of infected patients, and addresses preemptive management after unintentional laboratory exposure.
Structured evidence summary
Research question
This guideline addresses clinical management questions across the spectrum of coccidioidomycosis syndromes, from initial pulmonary infection to pulmonary and extrapulmonary complications, and includes recommendations for special at-risk populations and postexposure management.
Study design
Clinical practice guideline developed by the Infectious Diseases Society of America.
Population and setting
Patients with coccidioidomycosis, including those with residence in or recent travel to endemic areas of the southwestern United States and elsewhere in the Western Hemisphere, with additional focus on special at-risk populations.
Main findings
The guideline organizes recommendations for managing the clinical spectrum of coccidioidomycosis, noting that initial pulmonary infection eventually resolves with or without antifungal therapy, and provides management strategies for complications and preemptive approaches for at-risk groups and laboratory exposures.
Public-health relevance
The guideline emphasizes that residence in and recent travel to endemic areas are critical for accurate recognition of infected patients, and addresses preemptive management after unintentional laboratory exposure.
Important limitations
Guidelines cannot always account for individual patient variation and are not intended to supplant physician judgment regarding particular patients or special clinical situations. This summary is limited to the supplied single-article abstract and metadata; the original guideline document is required for decision-grade interpretation of specific clinical recommendations.
GIDS interpretation
This guideline would be discoverable through classifier links to coccidioidomycosis disease surveillance, United States geographic monitoring, and health policy or treatment topic filters, providing clinical context for suspected or confirmed cases identified through routine or enhanced surveillance.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.